Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Lupus Institute
Colleague Insights
Conferences
Resource Library
Sign in
Join now

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Rheumatology. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

story of the week
Published in Rheumatology

Journal Scan / Research · August 08, 2022

Upadacitinib for Active Ankylosing Spondylitis Refractory to Biological Therapy

Annals of the Rheumatic Diseases

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Walter Maksymowych MB ChB, FACP, FRCP(C)

Annals of the Rheumatic Diseases
Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial
Ann. Rheum. Dis 2022 Jul 04;[EPub Ahead of Print], D van der Heijde, X Baraliakos, J Sieper, A Deodhar, RD Inman, H Kameda, X Zeng, Y Sui, X Bu, AL Pangan, P Wung, IH Song

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Recently Updated